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Abstract: We present a silica nanoparticle (SNP) functionalized with 
polyphosphate (polyP) that accelerate the body’s natural clotting 
process. SNPs initiate the blood clotting system’s contact pathway; 
short-chain polyP accelerates the common pathway via rapid 
formation of thrombin. This enhances the overall blood-clotting 
system, both by accelerating fibrin generation and by facilitating the 
regulatory anticoagulation mechanisms essential for hemostasis. 
Analyzing the clotting properties of bare SNPs, bare polyP, and 
polyP-functionalized SNPs in plasma, demonstrates that attaching 
polyP to SNPs to form polyP-SNPs creates a substantially enhanced 
synergistic effect that lowers clotting time and increases thrombin 
production at low concentrations when compared to bare SNPs or 
polyP alone. PolyP-SNP even retains its clotting function at ambient 
temperature. The polyP-SNP system has the potential to significantly 
improve trauma treatment protocols and outcomes in hospital and 
prehospital settings. 
Controlling hemorrhage is a major focus in the treatment and 
stabilization of many trauma patients. Uncontrolled blood loss is the 
leading cause of battlefield deaths, despite the fact that less than 
5 % of soldiers who subsequently reach a hospital die of their 
wounds.
[1]
 In civilian hospitals, hemorrhage results in 15-25 % of 
trauma deaths.
[2]
 These data suggest that treatment should focus on 
stopping bleeding prior to hospital arrival. Bleeding management is 
currently aimed at volume resuscitation and surgical intervention to 
limit blood loss.
[3]
 However, these measures often do not address 
the source or mechanism of the bleeding and ultimately can limit the 
possible options to control it, especially in the prehospital setting. 
Currently, there are three major approaches for controlling 
prehospital hemorrhage. The oldest method employs 
mechanical devices that compress the wound to minimize the 
area through which blood can escape the damaged vessel.[4] 
Agents such as kaolin or chitosan(Scheme 1) are useful as field 
therapeutics for management of external hemorrhage and are 
widely utilized by military forces as a first-response treatment.[5] 
Unfortunately, use of these agents may be associated with 
further damage to some body tissues.[6] Furthermore, these 
compounds cannot be administered systemically and therefore 
lack utility for internal injuries with an intrinsic non-compressible 
hemorrhage. 
Recombinant human Factor VIIa (rFVIIa) is currently 
licensed for the management of bleeding episodes in patients 
with hemophilia and certain cases of warfarin 
overanticoagulation. Off-label use of rFVIIa is also commonly 
seen in certain other hemorrhagic conditions.[7] Although 
anecdotal reports of clinical response abound, a significant 
number of concerns regarding safety remain, due to reported 
thrombotic complications.[7] Drug storage requirements and the 
extreme cost of recombinant protein medication further limit field 
use.[8] 
 
scheme 1. Simplified coagulation cascade. SNP surface induces the 
activation of FXII, while short-chain polyP enhances the rates of activation of 
FV and FXI leading to an earlier thrombin burst. Rapid thrombin generation 
leads to back-activation of FXIa, accelerating the coagulation cascade, as well 
as facilitating increased activity in the anticoagulation pathway, which is 
designed to limit the spread of coagulation to uninjured vessels. Kaolin acts 
only to activate FXII via the intrinsic pathway. 
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The ideal agent to control non-compressible hemorrhage in 
the prehospital setting would have the following properties: (1) 
long shelf-life and stability in weather extremes, (2) reasonable 
cost, (3) promote key functions of the blood clotting system at 
the injury site including coagulation, regulatory anti-coagulation 
and fibrin formation,(4) lack of off-target adverse effects. Such 
an agent could initiate treatment during the transport phase 
when the patient is at the greatest risk for exsanguination. We 
propose that targeted short-chain polyphosphate-laden silica 
nanoparticles (polyP-SNPs) have the potential to fulfill these 
requirements. 
Because it accelerates rather than initiates endogenous 
coagulation enzyme production, short-chain polyP is a 
reasonable candidate for the management of hemorrhage.[9] 
Delivery of a polyP payload on a nanoparticle carrier could 
potentially be optimized to target the site of injury while 
minimizing the impact on the systemic circulation. Effective 
targeting and control would in theory minimize the risk of 
thrombotic complications that limit procoagulant therapy. In 
addition to the potential for better biosystem safety, the 
production cost for polyP is low compared to that of recombinant 
proteins. Upon attachment to inorganic oxides, polyP also has 
the potential for long-term stability under a variety of storage 
conditions. 
In response to an injury, human platelets secrete short-chain 
polyP of approximately 60-100 monomers. Platelet-secreted 
polyP has a variety of wound-healing therapeutic effects, 
including enhanced activation of factors XI and V, which 
ultimately leads to enhanced factor X activity, and limitation of 
the activity of tissue factor pathway inhibitor, which results in 
accelerated thrombin generation.[10] The incorporation of polyP 
also impacts clot structure and leads to resistance to 
fibrinolysis.[11]  Due to a ~90 minute half-life in plasma, the 
procoagulant effects are temporally limited.[10-12] This 
endogenous metabolism of polyP offers much better 
biocompatibility than currently available agents such as kaolin, 
which are not metabolized. 
Whereas long-chain polyP is a potent activator of the contact 
pathway, short-chain polyP released from platelets has relatively 
poor capacity to activate factor XII.[9]  We employed relatively 
short-chain polyP for these studies in order to maximize the 
enhancement of downstream coagulation enzymatic steps 
(common pathway), while minimizing contact pathway activation. 
As noted above, platelets serve as a polyP delivery agent, 
secrete procoagulants and clotting factors that promote blood 
coagulation, and initiate the formation of a clot-dissolving 
enzyme that degrades blood clots during the healing process. In 
our studies following up on the extensive research originally 
carried out by the Morrissey group,[9-12] we use free polyP as a 
benchmark.  In the research we report here, delivery agent 
bifunctionality is introduced by using SNPs as a procoagulant 
carrier for the polyP. 
Silica is generally considered to be a non-toxic material, and 
it is often used in drug delivery studies.[13]  However, due to its 
negative surface charge, silica is also a contact activator.[5a,14] 
Consequently, the ideal construction of a polyP-bearing silica 
nanoparticle would shield the silica from exposure to the 
systemic circulation, with targeting and exposure of the silica 
carrier surface and polyP at the site of internal hemorrhage.  
Current materials used for treating external hemorrhage 
generally contain particles in the micrometer range, which are 
too large to easily traverse capillaries and unsuitable for use as 
intravenous therapeutics.[15] We consequently developed an 
approach for the synthesis of 50 - 100 nm diameter particles (Fig. 
1L, Table 1).[5a,15] 
To attach the highly anionic polyP to an oxide, we followed 
the model of Lorenz et al. who used zirconia, which like silica 
has a negative surface potential, as the scaffold for applications 
in protein separation and purification.[16] This attachment 
strategy exploits the Lewis acid properties of an oxide surface to 
bind polyP, overcoming the electrostatic repulsion.[17] 
  
Figure 1. (Left) TEM images of polyP-SNPs; (Right) 
31
P NMR spectrum of 
digested polyP-SNPs shows evidence of phosphorous. 
31P NMR and surface charge change qualitatively 
demonstrated polyP attachment. PolyP-SNPs were digested in 
acid to break down polyP into phosphate monomers. 31P NMR 
tests on the digested sample detected the presence of 
phosphorous. The change in surface charge also suggested the 
presence of polyP in undigested polyP-SNP (Table 1, SI Fig. 2). 
At physiological pH in phosphate buffered saline solution (PBS), 
both SNPs and polyP display a negative surface charge. In 
deionized water, the SNP surface charge ranged from -15 to -25 
mV (Table 1, SI Fig. 2R). In simulated body fluid (SBF) at 
physiological pH, SNPs had a surface charge of -50 to -60 mV. 
PolyP is negatively charged at physiologic pH due to a pKa1 
between pH 1-2 (for all internal phosphates) and pKa2 between 
pH 7.2 and 8.2 (for the two terminal phosphates).[18] Upon 
functionalization of polyP to the SNP surface, the zeta potential 
of the polyP-SNP decreased from -20 to -30 mV to roughly -40 
to -50 mV in water, confirming the attachment of the polyP. In 
SBF, both particles exhibited a strongly negative charge below -
45 mV. 
Table 1. The zeta potential and surface charge of the particles change 
when dispersed in water or phosphate buffered saline solution, pH 7.4. 
Compound, Medium
 [a]
 Zeta Potential (µV) Size (nm) 
SNP, H2O -24.4 ± 0.3 55.97 ± 2.19 
SNP, PBS -52.5 ± 2.1 74.00 ± 6.24 
PolyP-SNP, H2O -44.3 ± 0.3 53.79 ± 1.75 
PolyP-SNP, PBS -52.0 ± 3.2 78.18 ± 2.86 
To quantify the polyP loaded on the SNP surface, the 
digested phosphate solutions were measured using both a 
malachite green assay and inductively coupled plasma atomic 
emission spectroscopy (ICP-AES). Malachite green identified 
concentrations of 56, 26, and 23 nmol PO3/mg SNP. ICP-AES 
determined the 26 nmol PO3 sample had 29.6 nmol PO3/mg 
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SNP. Assuming each polyP chain has 70 PO3 monomers, these 
data suggest 100 – 200 polyP molecules are attached to each 
SNP. 
By not using tissue factor to initiate clotting, we focused our 
clotting assays on the intrinsic and contact activation pathways. 
Negatively charged particles, such as the aluminosilicate kaolin 
(QuikClot® Combat GauzeTM) used for external injuries, activate 
the contact pathway,.[4,5a] Because it is a poor clot initiator, polyP 
attachment shields SNPs in the systemic circulation, which is 
beneficial for use to control haemorrhage intravenously. We 
measured the impact of both bare SNPs and polyP-SNPs on clot 
time using thromboelastography (TEG, Fig. 2T, SI Fig. 4, 5) on 
pooled normal plasma (PNP). Both particles decreased the time 
to initial clot formation (R) in a concentration-dependent manner, 
with polyP-SNP being more potent at concentrations below 0.5 
mg/mL. The clot time reported in figures 2 and 4 refers to the 
time to initial clot formation, which is key in illustrating how 
polyP-SNP successfully accelerates clotting. The agent used did 
not affect the overall clot size formed, only the time required to 
reach peak clot size. However, polyP has previously been 
shown to improve overall clot formation, in part by limiting the 
effect of fibrinolysis in plasma containing tissue plasminogen 
activator.[11-12] 
  
 
Figure 2. (Top) PolyP-SNP cuts clot time (R value using TEG) roughly in half 
versus SNP below 0.3 mg/ml. (Bottom) PolyP loaded onto silica lowers clot 
time compared to bare polyP when measured by fibrometry. 
Next we evaluated the procoagulant activity of polyP-SNPs 
formed with differing loads of polyP. The ability to promote 
coagulation was measured by adding polyP-SNP or polyP in 
solution to PNP. Coagulation was evaluated by measuring time 
to clot formation on a fibrometer (Fig. 2B). In comparing polyP 
payload, polyP-SNPs were more potent at activating the contact 
pathway than polyP in solution. 
 
Figure 3. (Top) Thrombin generation is more rapid with polyP-SNP than bare 
SNP. (Bottom) polyP-SNPs are able to generate a rapid thrombin burst even 
at low concentrations. Thrombin generation is measured using a thrombin-
sensitive fluorescent dye. 
To further explore the relative activities of our materials, we 
evaluated the ability of the materials to generate thrombin, the 
terminal enzyme of the coagulation cascade and the primary 
determinant of the rate of fibrin formation.[9a] PolyP-SNP again 
substantially outperformed its bare counterpart (Fig. 3T). 
We next evaluated whether polyP-SNPs were able to 
enhance the generation of downstream coagulation enzymes 
(common pathway). We eliminated any potential impact on 
contact activation by utilizing factor XII-deficient plasma and 
initiating coagulation using a small amount of relipidated tissue 
factor (LTF, 63 pM). As expected, bare SNPs did not affect TEG 
clot time in this system (Fig. 4T). In contrast, polyP-SNP did 
shorten the time to physical clot formation. This indicates that 
the polyP is accessible for binding to the relevant downstream 
coagulation proteins. Additionally, this response could also be 
evaluated in the clinical setting by comparing tests such as 
prothrombin time (PT) and partial thromboplastin time (PTT). 
 
COMMUNICATION          
 
 
 
 
 
Figure 4. (Top) Adding PolyP-SNP to LTF shortens clot time in FXII-deficient 
plasma compared to LTF only or LTF + SNP. LTF required to initiate clotting. 
(Bottom) PolyP-SNP suspended in aqueous solution retains its procoagulant 
function after weeks of storage at ambient conditions. 
 One of the problems facing emergency medical personnel 
is that current intravenous treatments have a significantly short 
half-life at ambient temperature. Even pure polyP nanoparticles 
remain stable for hours.[9b] In comparison, attaching polyP to 
silica greatly enhanced the stability and procoagulant function of 
polyP from hours to weeks. After bench-top storage at room 
temperature in both powder and aqueous suspensions, polyP-
SNP clotting times remained constant for weeks (Fig. 4B). The 
strong negative surface charge of polyP-SNPs also minimized 
aggregation in aqueous suspensions over the same time period. 
Injectable drugs with long-term shelf-life can be used by 
emergency medical personnel prior to hospital arrival without 
concern that the particles will degrade without refrigeration. This 
suggests that the polyP-SNP system may be the first prehospital 
intravenous injection designed to treat internal injuries by 
accelerating the clotting system at bleeding sites. 
In this study, we successfully attached polyP to the surface 
of small-diameter SNPs and demonstrated that these polyP-
SNPs are more potent than bare SNPs at promoting coagulation, 
likely due to polyP’s ability to accelerate the common pathway 
for active clotting processes.  PolyP-SNPs, like polyP in solution, 
are able to enhance downstream coagulation reactions resulting 
in a shorter time to clot formation. Even after long-term storage 
at regular room temperature, the polyP-SNP system retained its 
procoagulant ability. The polyP-SNP construct is consequently 
promising as a prohemostatic agent. Further exploration of 
methods to limit contact activation in vivo will be necessary for 
use as a systemic agent. 
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